Volcano Corp. Stays Neutral - Analyst Blog
June 10 2011 - 1:33PM
Zacks
Recently, we reaffirmed our Neutral recommendation on
Volcano Corporation (VOLC) with a target price of
$32.00.
Volcano Corporation reported an EPS of 2 cents in the first
quarter of fiscal 2011 compared to the year-ago quarter’s net
loss of 8 cents per share. The earnings were better than the
Zacks Consensus Estimate of a loss of 2 cents per share.
Revenues increased 22% year-over-year to reach $81 million
during the quarter with strong growth in Intravascular Ultrasound
(IVUS) and Functional Measurement (FM) single-procedure
disposables. Revenues were higher than the Zacks Consensus Estimate
of $80 million.
The company also announced a supply agreement with ev3, a
Covidien (COV) company to use its IVUS technology
in the latter’s plaque excisionsystems.
Volcano has a strong portfolio, which should generate growth for
the company in the long term. Full market launch of the Vibe
vascular imaging balloon catheter in Europe that commenced in 2010
has been progressing well.
Volcano has received encouraging feedback from clinicians
regarding its efficacy and ease of use. Although it is not yet
approved in the US, the company is working hard to get the product
approved (expected in 2012).
During the quarter, the company recorded a 40% growth in IVUS
disposable revenue in Japan, representing a full quarter after the
Fukuda Denshi transition. Japan is the largest IVUS market in the
world and we believe the transition to a direct sales force will
boost top- and bottom-line growth in the long run.
olcano Corporation also experienced some product developments in
Japan in the recent past. The company received clearance to market
both, the Eagle Eye Platinum digital IVUS catheter and the
PrimeWire Prestige FFR guide wire in Japan. Full market release of
both products is expected in the second quarter. Moreover, the
company is excited about the potential of Vibe in Japan
The recent natural disaster in Japan negatively impacted
revenues by $1 million during the quarter. Volcano Corporation
expects an additional impact of $4 million in the next two quarters
with normalcy expected to set in by the fourth.
As a result, the company lowered its revenue and EPS guidance
for 2011 by $5 million to $342–$347 million and by $0.03 to
$0.19−$0.21, respectively. Although the company expects business to
get back to its normal levels by the fourth quarter, any hiccup in
the recovery process might lead the company to miss its
guidance.
Moreover, Volcano Corporation faces intense competition for both
its IVUS range of products and its FM products from players such as
Boston Scientific (BSX) and St Jude
Medical (STJ).
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
COVIDIEN PLC (COV): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
VOLCANO CORP (VOLC): Free Stock Analysis Report
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From May 2024 to Jun 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2023 to Jun 2024